Constitutive Knockout

Mrp1 Constitutive Knockout Mouse Model
EZcohort® Models
The easiest way to acquire and breed cryopreserved GEMs

FVB Background

  • Model #
  • Genotype
  • Nomenclature
  • 1486-F
    FVB.129P2-Abcc1atm1Bor N12
  • 1486-M
    FVB.129P2-Abcc1atm1Bor N12
  • Carries a disruption of the Abcc1a (ATP-binding cassette, sub-family C (CFTR/MRP), member 1a) gene that encodes an ATP-dependent drug-extruding transporter formerly known as Mrp1
  • Abcc1a encodes ATP-dependent transport proteins for glutathione-, glucuronide-, or sulfate-conjugated substrates, including endogenous compounds such as steroids and leukotrienes as well as xenobiotics drugs
  • One of a family of ATP-binding cassette genes which encode multi-drug resistance proteins which confers resistance to a range of cytotoxic drugs
  • Exhibits normal fertility and viability but is deficient in functional MRP1 protein, leading to a 95% reduction in cellular transport of glutathione-conjugated substrates and decreased transport of leukotrienes C4, known inflammatory mediators
  • Exhibits an impaired inflammatory stimulus response and hypersensitivity to the anti-cancer drug, etoposide and vincristine
  • Useful for studying the role of ATP-dependent transporters in mediating inflammatory response and to test drug disposition
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

FVB Background


The Mrp1 mouse was developed in the laboratory of Piet Borst at the Netherlands Cancer Institute. The model was created by targeting the Abcc1a gene in 129/Ola derived E14 ES cells and injecting the targeted cells into blastocysts. Resultant chimeras were backcrossed to FVB/N for six generations (N6). Taconic received stock in 1999. After additional backcrosses to FVB/NTac to N12, the line was embryo derived. Heterozygotes were intercrossed to generate homozygotes. The colony is maintained through incrossing of homozygous mice.


Wild type for Nnt mutation; carries Pde6brd1 mutation





Initial Publication:

Wijnholds J, Evers R, van Leusden MR, Mol CAAM, Zaman GJR, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, Borst P. (1997) Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.; Nature Med, 3:1275-9.

Conditions of Use for EZcohort® Models
EZcohort® models are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic Biosciences, Inc. (Taconic) sells EZcohort® models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased EZcohort® models in consideration of purchasers' acknowledgement of and agreement to Taconic's Terms and Conditions for the Sale of Products and the following conditions of use:

  • Title to EZcohort® models and biological materials derived from them remains with Taconic.
  • EZcohort® models will be used for research purposes only.
  • EZcohort® models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Breeders from deliverables can be used for propagation of EZcohort® models or to cross to other strains.
  • Continuation of breeding and crossbreeding of EZcohort® models outside Taconicis permitted for a term of three years post-purchase of the EZcohort® models and is subject to annual confirmation of these EZcohort® Conditions of Use.

Continuation of breeding and crossbreeding after the three year term will require renewal of the EZcohort® Conditions of Use and payment of a fee.